Evaluation of the relative performance of drug-induced skeletal muscle injury biomarkers in rats

Toxicological Sciences

Volumn 150, Issue 1, 2016, Pages 247-256

  Burch, Peter M ^a   Hall, David Greg ^b   Walker, Elizabeth G ^c   Bracken, William ^d   Giovanelli, Richard ^a   Goldstein, Richard ^a   Higgs, Richard E ^b   King, Nicholas M P ^c   Lane, Pamela ^e   Sauer, John Michael ^c   Michna, Laura ^e   Muniappa, Nagaraja ^e   Pritt, Michael L ^b   Vlasakova, Katerina ^e   Watson, David E ^b   Wescott, Debra ^g   Zabka, Tanja S ^f   Glaab, Warren E ^e  

^a PFIZER INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c CRITICAL PATH INSTITUTE   (United States)

^d Abbvie Inc   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f GENENTECH INC   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

Biomarkers; Creatine kinase M isoform; Fatty acid binding protein 3; Myosin light chain 3; Qualification; Skeletal muscle; Skeletal troponin I

Indexed keywords

1 NAPHTHYL ISOTHIOCYANATE; 4,4' METHYLENEDIANILINE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; BROMOBENZENE; CERIVASTATIN; CISPLATIN; CREATINE KINASE; CREATINE KINASE M; DOXORUBICIN; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 3; FURAN; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 3; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; THIOACETAMIDE; TROPONIN I; UNCLASSIFIED DRUG; CREATINE KINASE MM; DRUG; FABP3 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG INDUCED SKELETAL MUSCLE INJURY; EVALUATION STUDY; FEMALE; HISTOPATHOLOGY; INJURY SEVERITY; MALE; MUSCLE ATROPHY; MUSCLE NECROSIS; MYOPATHY; NONHUMAN; PATIENT SAFETY; RAT; SENSITIVITY AND SPECIFICITY; ANIMAL; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; FISCHER 344 RAT; METABOLISM; METHODOLOGY; MUSCLE DISEASE; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT; WISTAR RAT;

ANIMALS; BIOMARKERS; CREATINE KINASE, MM FORM; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACID-BINDING PROTEINS; FEMALE; MALE; MUSCLE, SKELETAL; MUSCULAR DISEASES; MYOSIN LIGHT CHAINS; PHARMACEUTICAL PREPARATIONS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; TROPONIN I;

EID: 84963877187     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfv328     Document Type: Article

References (22)

1. Apple, F. S., Rogers, M. A., Sherman, W. M., Costill, D. L., Hagerman, F. C., and Ivy, J. L. (1984). Profile of creatine kinase isoenzymes in skeletal muscles of marathon runners. Clin. Chem. 30, 413-416.
2. Berna, M. J., Zhen, Y., Watson, D. E., Hale, J. E., and Ackermann, B. L. (2007). Strategic use of immunoprecipitation and LC/MS/ MS for trace-level protein quantification: Myosin light chain 1, a biomarker of cardiac necrosis. Anal. Chem. 79, 4199-4205.
3. Burch, P. M., Pogoryelova, O., Goldstein, R., Bennett, D., Guglieri, M., Straub V., Bushby, K., Lochmüller, H., and Morris, C. (2015). Muscle-derived proteins as serum biomarkers for monitoring disease progression in three forms of muscular dystrophy. J. Neuromuscular Dis. 2, 241-255.
4. Burkhardt, J. E., Pandher K., Solter, P. F., Troth, S. P., Boyce, R. W., Zabka, T. S., and Ennulat, D. (2011). Recommendations for the evaluation of pathology data in nonclinical safety biomarker qualification studies. Toxicol. Path. 39, 1129-1137.
5. European Medicines Agency (EMA). (2012). Guideline on bioanalytical method validation. Available at: http://www.ema. europa.eu/docs/en_GB/document_library/Scientific_guide line/2011/08/WC500109686.pdf. Accessed May 22, 2013.
6. European Medicines Agency (EMA). (2015). Letter of Support for skeletal muscle injury biomarkers. Available at: http://www. ema.europa.eu/docs/en_GB/document_library/Other/2015/ 03/WC500184458.pdf. Accessed May 20, 2015.
7. Food and Drug Administration (FDA). (2001). Guidance for Industry: Bioanalytical Method Validation-ICH-Q2A. Available at: http://www.fda.gov/downloads/Drugs/. / Guidances/ucm070107.pdf. Accessed May 22, 2013.
8. Food and Drug Administration (FDA). (2015). Biomarker Letter of Support for plasma/serum Myl3, skeletal muscle troponin I (sTnI), Fabp3, and creatine kinase, muscle type (CK-M, the homodimer CK-MM). Available at: http://www.fda.gov/down loads/Drugs/DevelopmentApprovalProcess/ DrugDevelopmentToolsQualificationProgram/UCM432653. pdf. Accessed May 20, 2015.
9. Foster, G. E., Nakano, J., Sheel, A. W., Simpson, J. A., Road, J. D., and Reid, W. D. (2012). Serum skeletal troponin I following inspiratory threshold loading in healthy young and middleaged men. Eur. J. Appl. Physiol. 112, 3547-3558.
10. Glatz, J. F. C., Schaap, F. G., Binas, B., Bonen, A., van der Vusse, G. J., and Luiken, J. J. F. P. (2003). Cytoplasmic fatty acid-binding protein facilitates fatty acid utilization by skeletal muscle. Acta Physiol. Scand. 178, 367-371.
11. Hanley, J. A., and McNeil, B. J. (1983). A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148, 839-843.
12. Lee, D. S., and Vasan, R. S. (2005). Novel markers for heart failure diagnosis and prognosis. Curr. Opin. Cardiol. 20, 201-210.
13. McLaurin, M. D., Apple, F. S., Voss, E. M., Herzog, C. A., and Sharkey, S. W. (1997). Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: Evidence of cardiac troponin T expression in skeletal muscle. Clin. Chem. 43, 976-982.
14. Mullen, A. J., and Barton, P. J. (2000). Structural characterization of the human fast skeletal muscle troponin I gene (TNNI2). Gene 25, 313-320.
15. Nikovits, W., Jr, Mar, J. H., and Ordahl, C. P. (1990). Muscle-specific activity of the skeletal troponin I promoter requires interaction between upstream regulatory sequences and elements contained within the first transcribed exon. Mol. Cell. Biol. 10, 3468-3482.
16. Pencina, M. J., D'Agostino, R. B., and Vasan, R. S. (2010). Statistical methods for assessment of added usefulness of new biomarkers. Clin. Chem. Lab. Med. 48, 1703-1711.
17. Pritt, M. L., Hall, D. G., Recknor, J., Credille, K. M., Brown, D. D., Yumibe, N. P., Schultze, A. E., and Watson, D. E. (2008). Fabp3 as a biomarker of skeletal muscle toxicity in the rat: Comparison with conventional biomarkers. Toxicol. Sci. 03, 382-396.
18. Simpson, J. A., Labugger, R., Collier, C., Brison, R. J., Iscoe, S., and Van Eyk, J. E. (2005). Fast and slow skeletal troponin I in serum from patients with various skeletal muscle disorders: A pilot study. Clin. Chem. 51, 966-972.
19. Sun, D., Hamlin, D., Butterfield, A., Watson, D. E., and Smith, H. W. (2010). Electrochemiluminescent immunoassay for rat skeletal troponin I (Tnni2) in serum. J. Pharmacol. Toxicol. Methods 61, 52-58.
20. Tonomura, Y., Matsushima, S., Kashiwagi, E., Fujisawa, K., Takagi, S., Nishimura, Y., Fukushima, R., Tori, M., and Matsubara, M. (2012). Biomarker panel of cardiac and skeletal muscle troponins, fatty acid binding protein 3 andmyosin light chain 3 for the accurate diagnosis of cardiotoxicity and musculoskeletal toxicity in rats. Toxicology 302, 178-189.
21. Vassallo, J. D., Janovitz, E. B., Wescott, D. M., Chadwick, C., Lowe- Krentz, L. J., and Lehman-McKeeman, L. D. (2009). Biomarkers of drug-induced skeletal muscle injury in the rat: Troponin I and myoglobin. Toxicol. Sci. 111, 402-412.
22. Wallimann, T., Wyss, M., Brdiczka, D., Nicolay, K., and Eppenberger, H. M. (1992). Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: The 'phosphocreatine circuit' for cellular energy homeostasis. Biochem. J. 281, 21-40.